BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 23536495)

  • 1. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma.
    Berry K; Ioannou GN
    Liver Transpl; 2013 Jun; 19(6):634-45. PubMed ID: 23536495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center.
    Huo TI; Huang YH; Lui WY; Wu JC; Lee PC; Chang FY; Lee SD
    Oncol Rep; 2004 Feb; 11(2):543-50. PubMed ID: 14719097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma.
    Merani S; Majno P; Kneteman NM; Berney T; Morel P; Mentha G; Toso C
    J Hepatol; 2011 Oct; 55(4):814-9. PubMed ID: 21334400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Kim IH; Yi NJ; Lee KU
    Surgery; 2007 May; 141(5):598-609. PubMed ID: 17462459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
    Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
    Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
    Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma.
    Ho CM; Wu CY; Lee PH; Lai HS; Ho MC; Wu YM; Hu RH
    Ann Surg Oncol; 2013 Aug; 20(8):2526-33. PubMed ID: 23504121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
    Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
    World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
    Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
    Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
    Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
    Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
    Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer.
    Grat M; Kornasiewicz O; Hołówko W; Lewandowski Z; Zieniewicz K; Paczek L; Krawczyk M
    Transplant Proc; 2013 Jun; 45(5):1899-903. PubMed ID: 23769067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients.
    Lee YH; Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Chiou YY; Huo TI
    Aliment Pharmacol Ther; 2012 Sep; 36(6):551-9. PubMed ID: 22817677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
    Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
    Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
    Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.
    Giannini EG; Sammito G; Farinati F; Ciccarese F; Pecorelli A; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Gasbarrini A; Sacco R; Foschi FG; Missale G; Morisco F; Svegliati Baroni G; Virdone R; Trevisani F;
    Cancer; 2014 Jul; 120(14):2150-7. PubMed ID: 24723129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.